Wearable nasal technology

Rhinomed is a global medical device company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery.

Introducing RHINOSWAB

The world’s most comfortable nasal swab for COVID-19 and upper respiratory pathogens including influenza and RSV.


The happy way to swab children.

knows noses

Rhinomed is a wearable nasal technology company that seeks to radically improve the way you breathe, sleep, maintain your health, diagnose disease and take medication.

We create medical devices that are used by millions of people globally.

With a pipeline of compelling innovation focused on clear unmet clinical needs, we invite you to experience firsthand the difference Rhinomed can make to your way of life.

COVID-19 testing

Rhinoswab changes the way you collect a sample for diagnosis. Rhinoswab standardises the sampling process for COVID-19 and flu, making it easy and comfortable for clinician and patient alike.


Breathing clearly and easily is a key element in aerobic activity. Turbine is designed to assist athletes to overcome nasal obstruction and congestion by increasing airflow by up to 38%.


About half of the population snore. Mute dilates the nasal passages making nasal breathing easier, reducing mouth breathing and helping you to breathe more, snore less and sleep better.


A novel vapour delivery technology, Pronto Clear helps to clear a stuffy nose naturally through the delivery of a proprietary essential oil formulation.


Pronto Sleep uses our patented delivery technology to deliver a proprietary essential oil formulation that will help you to relax and sleep better naturally.

Clinical programs

Rhinomed’s wearable nasal technology supports a wide range of applications from stenting to diagnosis and nasal drug delivery.


  • Victorian Government orders Rhinoswab
    Rhinomed has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria’s testing capability. This follows the recent NSW Health Pathology … Read more
  • World’s first paediatric swab
    Rhinomed has created the world’s first nasal swab designed specifically for children — The Rhinoswab Junior™ Ethics approval has been received for a clinical trial to commence with the Murdoch … Read more
  • First Government Orders for Rhinoswab
    Rhinomed has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced … Read more
  • Rhinoswab Secures European CE Mark
    Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in … Read more
  • Appointment of Non Executive Director
    Rhinomed is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately. Assoc. Prof. McBain is the former Head … Read more
  • Key Studies Confirm Rhinoswab’s Superior Performance
    Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal … Read more